Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
Status:
Recruiting
Trial end date:
2023-05-30
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, phase II trial to test the efficacy of Ibrutinib in
combination with either Nivolumab or Cetuximab in the treatment of recurrent and/or
metastatic head an neck squamous cell carcinoma